Add BrightSurf on Google Email

Scientists uncover that albumin is prevented from crossing the placenta – open opportunities for design of long-acting biologic medicines with limited fetal exposure

Researchers uncover the placenta distinguishes between antibodies and albumin, allowing for the design of long-acting biologic medicines with reduced fetal exposure. Fusion of IgG antibodies to albumin inhibits transport across the placenta, enabling the development of safer treatments during pregnancy.

SourceUniversity of Oslo, Ullevaal University Hospital·JournalScience Immunology·DateAug 14, 2026

Antibody drugs with strong immune cell binding linked to allergic reactions

Researchers from Chiba University found that antibody therapeutics with stronger Fcγ receptor binding are more likely to be recognized as foreign and associated with higher anaphylaxis risk. High affinities for Fcγ receptors critical determinants of anaphylaxis, study suggests.

SourceChiba University·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateApr 8, 2026
CalDigit TS4 Thunderbolt 4 Dock

CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.

Hitting HIT: Heparin therapy

Researchers at LMU have discovered that inhibition of a specific enzyme can effectively prevent heparin-induced thrombocytopenia (HIT), a potentially life-threatening condition. The study shows that Btk inhibitors can block platelet activation and prevent the formation of harmful clots, offering a new promising therapeutic option for t...

SourceLudwig-Maximilians-Universität München·JournalBlood Advances·DateDec 20, 2019

It's Fab! A hidden touch of antibody

Antibodies recognize viruses and cancer cells via Fab arms, but now researchers know the Fab portion also directly binds to Fc receptors. This discovery opens up a new strategy for developing therapeutic antibodies with enhanced binding properties.

SourceNagoya City University·JournalScientific Reports·DateAug 21, 2019

Research shows how antibodies produce vaccine-like effect against tumors

Researchers at Rockefeller University have discovered two antibody-binding receptors on immune cells that work together to kill tumors and create a memory of them. The study found that targeting specific antigens with antibodies can lead to the formation of immunological memory, which can suppress future tumor growth.

SourceRockefeller University·JournalCell·DateMay 13, 2015

Newly identified immune receptor may activate B cells in autoimmunity

Researchers discovered a genetic variant that influences vaccine response and autoimmune disease risk. Individuals with this variant express an additional immune system receptor on their B cells, which activates antibody production, potentially leading to autoimmune diseases.

SourceUniversity of Alabama at Birmingham·JournalScience Translational Medicine·DateDec 18, 2013
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.